Tower Research Capital (TRC)’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-740
| Closed | -$35.4K | – | 5604 |
|
|
2025
Q3 | $35.4K | Sell |
740
-2,474
| -77% | -$68.6K | ﹤0.01% | 2795 |
|
|
2025
Q2 | $51.4K | Buy |
3,214
+846
| +36% | +$13.7K | ﹤0.01% | 2951 |
|
|
2025
Q1 | $36K | Buy |
2,368
+722
| +44% | +$11.6K | ﹤0.01% | 2467 |
|
|
2024
Q4 | $33.4K | Buy |
1,646
+1,232
| +298% | +$31K | ﹤0.01% | 2825 |
|
|
2024
Q3 | $10.6K | Sell |
414
-1,234
| -75% | -$20.6K | ﹤0.01% | 3732 |
|
|
2024
Q2 | $21.2K | Buy |
1,648
+240
| +17% | +$3.86K | ﹤0.01% | 3729 |
|
|
2024
Q1 | $32.2K | Buy |
1,408
+814
| +137% | +$28.7K | ﹤0.01% | 2592 |
|
|
2023
Q4 | $15.6K | Buy |
594
+498
| +519% | +$9.97K | ﹤0.01% | 3820 |
|
|
2023
Q3 | $2.7K | Buy |
+96
| New | +$2.81K | ﹤0.01% | 5113 |
|
|
2023
Q2 | – | Sell |
-867
| Closed | -$16K | – | 6361 |
|
|
2023
Q1 | $16K | Sell |
867
-36
| -4% | -$594 | ﹤0.01% | 3738 |
|
|
2022
Q4 | $9K | Buy |
903
+39
| +5% | +$627 | ﹤0.01% | 4275 |
|
|
2022
Q3 | $23K | Buy |
864
+527
| +156% | +$19.2K | ﹤0.01% | 3828 |
|
|
2022
Q2 | $15K | Sell |
337
-464
| -58% | -$36.6K | ﹤0.01% | 4094 |
|
|
2022
Q1 | $79K | Buy |
801
+730
| +1,028% | +$68.3K | ﹤0.01% | 2380 |
|
|
2021
Q4 | $11K | Sell |
71
-8
| -10% | -$1.18K | ﹤0.01% | 4459 |
|
|
2021
Q3 | $10K | Buy |
79
+73
| +1,217% | +$9.99K | ﹤0.01% | 4338 |
|
|
2021
Q2 | $1K | Buy |
+6
| New | +$919 | ﹤0.01% | 5267 |
|
Tower Research Capital (TRC)'s TRML Position: Q4 2025 in Review
Tower Research Capital (TRC) sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 740 shares — an estimated $35.4K sold.
Tower Research Capital (TRC) first reported a position in TRML in Q2 2021 and held it in 17 quarters. The position peaked at $79K in Q1 2022. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Tower Research Capital (TRC) reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Tower Research Capital (TRC) sold 740 Tourmaline Bio shares in Q4 2025, an estimated $35.4K.
- Tower Research Capital (TRC) first reported a position in Tourmaline Bio in Q2 2021 and held it in 17 quarters.
- Tower Research Capital (TRC)'s Tourmaline Bio position peaked at $79K in Q1 2022.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Tower Research Capital (TRC)'s 13F filing for Q4 2025, filed 17 Feb 2026.